Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo Given in Children Aged 6 Months to 5 Years With Recurrent Wheezing

NCT05857930 is registered in ClinicalTrials.gov with OM Pharma SA as lead sponsor.

NCT NCT05857930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05857930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess the Efficacy and Safety of Daily OM-85 Treatment vs. Placebo Given in Children Aged 6 Months to 5 Years With Recurrent Wheezing
Lead sponsor
OM Pharma SA
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 20, 2023
Completion date
September 30, 2026
Enrollment
296 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent wheezing, wheezing lower respiratory illness